Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.
Fidelity Advisor Biotechnology C FBTCX
- NAV / 1-Day Return 25.79 / +0.27 %
- Total Assets 1.9 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.730%
- Distribution Fee Level Low
- Share Class Type Level Load
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.00
- Turnover 73%
USD | NAV as of Sep 26, 2024 | 1-Day Return as of Sep 26, 2024, 10:13 PM GMT+0
Morningstar’s Analysis FBTCX
Will FBTCX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 58.6
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
AbbVie Inc | 18.21 | 329.4 Mil | Healthcare |
Amgen Inc | 9.43 | 170.7 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 7.01 | 126.8 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 4.72 | 85.5 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 4.53 | 82.0 Mil | Healthcare |
argenx SE ADR | 3.76 | 68.1 Mil | Healthcare |
Ascendis Pharma A/S ADR | 3.50 | 63.4 Mil | Healthcare |
Vaxcyte Inc Ordinary Shares | 2.61 | 47.2 Mil | Healthcare |
Cytokinetics Inc | 2.60 | 47.0 Mil | Healthcare |
Viking Therapeutics Inc | 2.26 | 40.9 Mil | Healthcare |